Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing

MLA

Yena Gan, et al. “Adebrelimab plus Chemotherapy vs. Chemotherapy for Treatment of Extensive-Stage Small-Cell Lung Cancer from the US and Chinese Healthcare Sector Perspectives: A Cost-Effectiveness Analysis to Inform Drug Pricing.” Frontiers in Pharmacology, vol. 14, July 2023. EBSCOhost, https://doi.org/10.3389/fphar.2023.1241130.

APA

Yena Gan, Fenghao Shi, He Zhu, Sheng Han, & Duoduo Li. (2023). Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1241130

Chicago

Yena Gan, Fenghao Shi, He Zhu, Sheng Han, and Duoduo Li. 2023. “Adebrelimab plus Chemotherapy vs. Chemotherapy for Treatment of Extensive-Stage Small-Cell Lung Cancer from the US and Chinese Healthcare Sector Perspectives: A Cost-Effectiveness Analysis to Inform Drug Pricing.” Frontiers in Pharmacology 14 (July). doi:10.3389/fphar.2023.1241130.